For full year 2023, the operating expenses for Tevogen Bio Inc were $8.8 million.
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
Tevogen's Chief Scientific Officer explains the company's oncology pipeline strategy as it relates to harnessing Cytotoxic T Lymphocytes to target cancers.
Mr. Shah, a Wall Street veteran with over 25 years of experience, brings broad leadership capabilities to Tevogen Bio.
The shares of Series A-1 Preferred Stock will be issued in the first quarter and will be convertible at a conversion price of $10.00, as opposed to the $4.
The shares of Series A-1 Preferred Stock will be issued in the first quarter and will be convertible at a conversion price of $10.00, as opposed to the $4.
Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant
Tevogen Congratulates Victor Sordillo on His appointment as Managing Director
Tevogen Prepares to Launch Crucial Genetic Predisposition Study
Tevogen Bio Is Looking Forward to Closing Its Transaction With Semper Paratus